FDA approves cidofovir for treatment of CMV retinitis. Food and Drug Administration
- PMID: 11363758
FDA approves cidofovir for treatment of CMV retinitis. Food and Drug Administration
Abstract
AIDS: In June 1996 the Food and Drug Administration (FDA) granted marketing clearance of cidofovir injection (Vistide) for the treatment of CMV retinitis in patients with AIDS. Two studies demonstrated cidofovir's ability to slow progression of CMV retinitis and were the basis for approval. Cidofovir is infused once a week for two weeks, then once every other week thereafter for maintenance. The major toxicity of cidofovir is renal impairment. Gilead has established a confidential Support Services Program to assist all patients seeking reimbursement or financial assistant.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical